Application DetailsImmunohistochemistry (IHC) and Western Blotting (WB). A concentration of 0.1-0.5 µg/mL is recommended for WB. Human CD40L has a predicted length of 261 residues and MW of 29 kDa. The observed size is 32 kDa. A concentration of 0.5-1.0 µg/mL is recommended to detect CD40L in formalin fixed and paraffin embedded tissues. Heat mediated antigen retrieval is required. Boiling the paraffin sections in 10mM citrate buffer, pH 6.0 for 20 minutes is recommended. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
TargetCD40 Ligand (CD40-L)
SpecificityThe specificity of this antibody has been confirmed by WB and IHC against the antigen. Human;
Target Host SpeciesHuman
Species ReactivityHuman
Antibody HostRabbit
Antibody TypePolyclonal
Antibody IsotypeIgG
ConjugateUnconjugated
Immunogen DescriptionA synthetic peptide (HRRLDKIEDERNLHEDFVF) corresponding to amino acid sequence 47-65 from the N-terminus of human CD40L.
Purity DescriptionAffinity purified on antigen column
Reconstitution InstructionsSpin vial briefly before opening. Reconstitute in 100 µL sterile-filtered, ultrapure water to achieve an antibody concentration of 1 mg/mL. Centrifuge to remove any insoluble material.
Storage InstructionsAfter reconstitution, aliquot and store at -20°C for a higher stability. Avoid freeze-thaw cycles.
Batch NumberPlease see item label.
Expiration Date12 months after date of receipt (unopened vial).
Alternative NamesCD40-L; TRAP; gp39; TRAM; CD154; Tumour necrosis factor ligand superfamily member 5; TNFSF5; CD40L;
Scientific BackgroundCD40L is the ligand for CD40, a member of the tumour necrosis factor (TNF) receptor superfamily. CD40L is expressed mainly on activated CD4+ T-lymphocytes as a single-pass type II membrane protein. Proteolytic processing of the membrane form results in a soluble secreted form of CD40L. Microglia and astrocytes interact via CD40 receptor and CD40 ligand.
General ReferencesKe Z.J. et al. CD40-CD40L interactions promote neuronal death in a model of neurodegeneration due to mild impairment of oxidative metabolism. Neurochem Int. 2005 Aug;47(3):204-1